课题基金 / 基金详情

Genetic polymorphism in the cytochrome P450-2C19 genes in Japanese patients with hepatocellu-lar carcinoma and hepatitis C infection

Genetic polymorphism in the cytochrome P450-2C19 genes in Japanese patients with hepatocellu-lar carcinoma and hepatitis C infection
日本肝细胞癌合并丙型肝炎感染患者细胞色素P450-2C19基因的遗传多态性
批准号:
08670629
负责人:
OHNISHI Akihiro
金额:
$1.15万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1996
资助国家:
日本
项目状态:
已结题
起止时间:
1996 至 1998

项目摘要

项目成果

OHNISHI Akihiro的其他基金

相似基金

相关文献

中文摘要
翻译
近年来,日本肝细胞癌(HCC)的发病率显著增加。大多数HCC患者在其背景疾病条件下患有丙型肝炎病毒(HCV)相关的慢性肝炎和肝硬化。在日本,66%至94%的HCC患者抗-HCV阳性且B病毒表面(HBs)抗原阴性,相反,在美国,HCC患者抗-HCV阳性的频率明显较低,40%的HCC患者抗-HCV阳性且B病毒表面(HBs)抗原阴性。这些结果表明存在物种差异(多态性)。由于环境致癌物部分影响肝细胞畸形(HCC)的过程,包括致癌物在内的各种异生素代谢能力的差异(日本人与高加索人)可以推断两国之间HCC发生率的差异。本研究采用基因分型法将药物代谢能力相关的P450亚型CYP 2C 19分为慢代谢型和强代谢型。用PCR-RFLP方法筛选外显子4和外显子5与药理学表型有很好的对应性。我们对30例HCV(+)肝癌患者的基因型调查显示,CYP 2C 19中30%为慢代谢型,70%为快代谢型。HCC中的这一结果与健康日本人的结果基本相似,此外,在临床环境中,这些患者的特征及其在快代谢型和慢代谢型之间的临床病程没有差异。
英文摘要
Recently there is a remarkable increase in population of hepatocellular carcinoma (HCC) in Japan. Most of the HCC patients have hepatitis C virus (HCV)-related chronic hepatitis and liver cirrhosis on their background disease condition. In Japan 66 to 94 percent in HCC patients are anti-HCV positive as well as negative hepatitis B virus surface (HBs) antigen, in contrast in United State there is markedly low frequency in HCC patients with positive anti-HCV and forty percent in HCC patients are anti-HCV positive and negative hepatitis B virus surface (HBs) antigen. These results indicate the presence of species difference (polymorphism). Since environmental carcinogen partly affect the process of hepatocyte malformation (HCC), the difference in metabolizing capability of various xenobitics including carcinogen (Japanese vs. Caucacian) may extrapolate such difference in HCC frequency between two countries. We analyzed and divided the drug metabolizing capability related P450 subtype CYP2C19 using genotyping into extensive and poor metabolizer. Pharmacogenotype method screening exon 4 and exon 5, using PCR-RFLP mehtod, has been reported to be well corresponding with pharmacological phenotype. Our genotype survey in 30 HCC patients with HCV(+) revealed 30% in poor metabolizer and 70% in extensive metabolizer in CYP2C19. This result in HCC was mostly similar to those in healthy Japanese, in addition such patients characteristics and their clinical course between extensive and poor metabolizer did not differ in clinical settings.
期刊论文(26)
专著(0)
科研奖励(0)
会议论文
Ohnishi A, et al.: "Prostaglandin production in cirrhosis and portal hypertension - experimental and clinical study" Hepatology Res. 131-141 (1997)
Ohnishi A 等人:“肝硬化和门静脉高压症中前列腺素的产生 - 实验和临床研究”肝病学研究。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Reeginald FF,Matzke GR,Adedoyin A,et al.: "Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes." Clin Pharmacol Ther. 62. 365-376 (1997)
Reeginald FF、Matzke GR、Adedoyin A 等人:“验证五种药物“匹兹堡鸡尾酒”方法,用于评估药物代谢酶的选择性调节。”
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Ohnishi A,et al.: "Prostaglandin production in cirrhosis and portal hypertension-experimental and clinical study" Hepatology Res. (in press). (1997)
Ohnishi A 等人:“肝硬化和门静脉高压症中前列腺素的产生 - 实验和临床研究”肝病学研究。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Nagai N,Kawakubo T,Kaneko F,Ishii M,Shinohara R,Saito Y,Ohnishi A et al.: "Pharmacokinetics and polymorphic oxidation of dextromethorphan in a Japanese population." Biopharm Drug Disposi. 17. 421-433 (1996)
Nagai N、Kawakubo T、Kaneko F、Ishii M、Shinohara R、Saito Y、Ohnishi A 等:“日本人群中右美沙芬的药代动力学和多晶型氧化”。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
共 23 条
    Portal Hypertension in Liver Cirrhosis and Drug Therapy
    • 批准号:
      01570411
    • 项目类别:
      Grant-in-Aid for General Scientific Research (C)
    • 资助金额:
      $0.64万
    • 财政年份:
      1989
    • 负责人:
      OHNISHI Akihiro
    • 依托单位:
    海外基金